Rennova Health 8K Regulation FD Disclosure | RNVA 9 Jan 13

Exhibit 99.1

CollabRx, Inc.

Informing Next Generation Healthcare

This presentation and the accompanying commentary include forward-looking
statements about CollabRx’ anticipated results that involve risks and uncertainties. Some
of the information contained in this presentation, including, but not limited to,
statements as to industry trends and CollabRx’ plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are subject to risks
and uncertainties that could cause actual results or events to differ materially from those
expressed or implied by such forward-looking statements. Any statements that are not
statements of historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or
future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar
expressions, identify certain of these forward-looking statements. Important factors
which could cause actual results to differ materially from those in the forward-looking
statements are detailed in filings made by CollabRx with the Securities and Exchange
Commission. CollabRx undertakes no obligation to update or revise any such forward-
looking statements to reflect subsequent events or circumstances.

NASDAQ CM: CLRX

¡ CollabRx’ Identity, Technology and Approach

¡ Platform for Knowledge Integration

¡ Products - Released and Under Development

¡ Healthcare Big Data Landscape

¡ Product Examples

¡ History, Management Team, Investment
Thesis

¡ Contacts

NASDAQ CM: CLRX

¡ Data Analytics Company, founded 2008

§ NASDAQ CM: July 12, 2012 through merger

¡ Product-Driven, using a unique combination of
Experts and Expert Systems to create a Proprietary
Knowledgebase

¡ Inform clinical decision-making with up-to-date,
actionable information on:

§ Biomarkers

§ Clinical Trials

§ Diagnostic Tests

§ Approved and Investigational New Drugs

¡ Focused today in Oncology for cancer diagnostics and
treatment planning

NASDAQ CM: CLRX

¡ Democratizing information by widely
distributing KOL-based insights

¡ “Agnostic” to any particular diagnostic test -
focused on relevant biomarkers, therapies,
drugs and trials

¡ Technology platform allows scaling in all
dimensions as new biomarkers identified

¡ Easy-to-use apps are key to accessibility and
usability

¡ Flexible and adaptable software-centric
company

NASDAQ CM: CLRX

Disease Targets

Drugs

Biomarkers

Clinical Trials

KNOWLEDGE INTEGRATION

Basic

Analytic

Synthetic

Capture and Integrate

Acquire or License

Create

Over 75 medical and scientific advisors
from leading institutions

"We're pleased to partner with
CollabRx to leverage the Internet
and social media to improve
cancer treatment planning in
melanoma and beyond.”

“Our collaboration with CollabRx
helps us deliver on our mission to
serve patients and fosters greater
communication between patients and
physicians which is vital to successful
treatment.”

NASDAQ CM: CLRX

Medical and Scientific Content

Dynamically updated

Best practice insights

Clinically relevant interpretations

Software and IT

Content delivery systems (“apps”)

Knowledge management systems

Decision support dashboards

Tools and Services

Artificial intelligence-based analytics

Interpretation of Big Data

Business intelligence (Pharma/Biotech)

NASDAQ CM: CLRX

Physician / Patient Care Team

Laboratory / Treatment Team

Therapy Finder Apps

Lung, Melanoma,
Colorectal,

Metastatic Breast,

Prostate, Pancreatic,

Acute Leukemia,

Sarcoma (including GIST),

GBE

Clinical Trial Matching App

Biomarker Reference Tool

Interpretation Portal

Path Lab App

Molecular
Diagnostics

Decision Support

Workflow and
Clinical
Course Issues

Lab Dashboard (EMR)

Clinical Interpretation App

Analytics on collected data - Mobile - Social Networking

NASDAQ CM: CLRX

Physician / Patient Care Team

Laboratory / Treatment Team

Sponsored Apps distributed
through On-Line Media:

*Based on reimbursed molecular PGx cancer test data from United Healthcare and
**Market Research.com #Internal Estimates Phase II/III no approved indications

Path Lab Product only
distributed by CollabRx:

Annual: 750,000 tests*

Ave. Price / Test ~ $3,000

Ave. Price / Report ~ $100-$200

TAM (today): $75M - $150M

Growth Rate: ~47% pa**

TAM (5 yr): $350M - $700M

Pharma Pre-Launch Marketing
budget per drug: ~ $50M #

Number of Drugs in Pipeline for
Common Incident Cancers ~ 50

% of Budget to On-Line 10%

TAM: $250M

NASDAQ CM: CLRX

Clinical
Support

Public
Awareness

Research
Support

Risk-
Stratification

Self-Care
Enabler

Data Generation

Data Interpretation

Decision Influence

Caris Life

Sciences

Medicine

Illumina

Roche 454

Legend: Industry Segment

Molecular Profiling / Dx

Clinical Reference

Predictive Analytics

My Cancer

Genome

Elsevier

Clinical

UpToDate

Gene Insight

Compendia

Biosciences

IBM

Watson

N-of-One

23 and Me

NASDAQ CM: CLRX

Caris Life

Clinical
Support

Public
Awareness

Research
Support

Risk-
Stratification

Self-Care
Enabler

Data Generation

Data Interpretation

Decision Influence

Foundation

Medicine

Illumina

Roche 454

Legend: Industry Segment

Molecular Profiling / Dx

Clinical Reference

Predictive Analytics

Compendia

Biosciences

IBM

23 and Me

NASDAQ CM: CLRX

•Expert insights on:

• Targets

• Treatment Guidelines

• Drugs

• Trials

• Literature.

•Links to:“

• Therapy Finder Advisor
and Board

• Learning About the
Science Behind the
Target

Treating Physician Portal

Patient
Portal

Test Result

(e.g.,ION TORRENT)

Content Engine

NASDAQ CM: CLRX

Drugs

Clinical Trials

“CollabRx has pioneered the development of a
scalable platform and process to provide
current, actionable, easily accessible, and highly
credible knowledge at the point of care to aid
physicians in developing a cancer treatment plan
based on tumor molecular profiles. We are
excited to include this key capability with our
molecular diagnostic tests.”

NASDAQ CM: CLRX

- Ronnie Andrews, President

Medical Sciences, Life Technologies Corporation

¡ Thomas Mika, Chairman & CEO

§ Tegal, IMTEC, Cresap, NSF

¡ George Lundberg, MD, Editor-In-Chief

§ American Medical Association, WebMD, Medscape

¡ Gavin Gordon, MBA, PhD, Head of Bus Dev &
Alliances

§ Harvard Medical School (professor; molecular
pathology)

¡ Smruti Vidwans, PhD, Chief Scientist

§ McKinsey & Company (GSK, Roche), MIT, UCSF

¡ Randy Gobbel, PhD, Head of Engineering

§ PARC (XEROX), XEROX, MDL, UCSD

NASDAQ CM: CLRX

¡ Founded 2008 by Silicon Valley Tech Entrepreneurs

§ Approximately $10M Invested Capital

§ Acquired by Tegal Corporation (TGAL) on July 12, 2012

¡ NASDAQ CM: CLRX (as of September 27, 2012)

§ Cash: $6.2M as of September 30, 2012 (Q2-FY’13)

§ Liabilities: $0.5M Note to Sellers

§ Net Operating Loss (Estimates): ~ $100M Federal; $50M California

§ ~ 2 Million Total Shares Outstanding; ~2.6M fully-diluted

¡ Convergence of multiple mega trends

¡ Disruptive technology and approach

¡ No comparable micro-caps in this sector

¡ Goals for CY2013 - Expand strategic partnerships, product
development, and product launches for initial revenue

NASDAQ CM: CLRX

Thomas R. Mika, Chairman & CEO

tmika@collabrx.com

415.248.5350 (office)

415-686-2198 (mobile)

Investor Relations Contact:

Robert Ferri
Robert Ferri Partners
580 California Street, Suite 1200
San Francisco, CA 94104
(415) 575-1589 (direct)

robert.ferri@robertferri.com

www.robertferri.com

CollabRx, Inc.

44 Montgomery St., Suite 800

San Francisco, CA 94104

www.collabrx.com

NASDAQ CM: CLRX

Rennova Health (RNVA) 8-KRegulation FD Disclosure